Last reviewed · How we verify

Ad5.F35-hGUCY2C-PADRE vaccine

Thomas Jefferson University · Phase 1 active Biologic Quality 3/100

Ad5.F35-hGUCY2C-PADRE vaccine is a Biologic drug developed by Thomas Jefferson University. It is currently in Phase 1 development. Also known as: Ad5/F35-hGCC-PADRE, Adenovirus 5/F35-HGCC-PADRE.

At a glance

Generic nameAd5.F35-hGUCY2C-PADRE vaccine
Also known asAd5/F35-hGCC-PADRE, Adenovirus 5/F35-HGCC-PADRE
SponsorThomas Jefferson University
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ad5.F35-hGUCY2C-PADRE vaccine

What is Ad5.F35-hGUCY2C-PADRE vaccine?

Ad5.F35-hGUCY2C-PADRE vaccine is a Biologic drug developed by Thomas Jefferson University.

Who makes Ad5.F35-hGUCY2C-PADRE vaccine?

Ad5.F35-hGUCY2C-PADRE vaccine is developed by Thomas Jefferson University (see full Thomas Jefferson University pipeline at /company/thomas-jefferson-university).

Is Ad5.F35-hGUCY2C-PADRE vaccine also known as anything else?

Ad5.F35-hGUCY2C-PADRE vaccine is also known as Ad5/F35-hGCC-PADRE, Adenovirus 5/F35-HGCC-PADRE.

What development phase is Ad5.F35-hGUCY2C-PADRE vaccine in?

Ad5.F35-hGUCY2C-PADRE vaccine is in Phase 1.

Related